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1. Introduction 
Interferon has been shown to affect several differ- 
ent cell functions. Part of its effect results in a decrease 
of virus multiplication in the cells. Other effects seem 
unrelated to the regulation of viral growth [ 1,2]. In 
some cases, the different effects of interferon on cells 
even appear to have opposing consequences. An 
example is the effect of interferon on cellular response 
to double-stranded (ds)RNA. Pretreatment of the 
cells by interferon (priming) increases significantly 
the ability of dsRNA to induce interferon synthesis 
[3], but on the other hand, interferon pretreated cells 
are also much more sensitive to the cytotoxic effect 
of dsRNA [4,5]. Interferon can also increase the cell 
damage, occurring during infection by some viruses, 
in spite of its ability to inhibit multiplications of these 
viruses [6&9]. This enhanced viral cytopathy might 
be related to an increased sensitivity of interferon- 
treated cells to the dsRNA produced during viral infec- 
tion [lo]. We have, therefore, searched for factors 
which could decrease the sensitivity of interferon- 
treated cells to the cytotoxicity of dsRNA without 
decreasing the antiviral action of interferon. This 
work shows that the cytotoxic effect is very sensitive 
to hormonal control. 
2. Methods and materials 
2.1. Labeling of cells with 51Cr and induction of lysis 
Confluent human foreskin fibroblasts of the strain 
FSI 1 (high interferon producer) were used. The cells 
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were grown on 16 mm tissue culture dishes in 
Dulbecco’s minimal essential medium with 10% fetal 
calf serum. Labeling was done by incubating for 24 h 
with sodium [“Crlchromate (10 &i/ml). The label 
was then removed and the cells were further incubated 
for 2 days with interferon (500 U/ml)ingrowthmedium 
which contained 10% fetal calf serum. Lysis was induced 
by rinsing the cells twice with serum-free medium, 
then incubating them, in the absence of serum, with a 
solution of poly(rI):(rC) (100 pg/ml) in growth medium. 
At various times after the addition of the dsRNA, 
samples were taken from the medium. Following the 
last sampling, the cells were detached by incubating 
in pancreatin solution (Gibco). The amount of “Cr in 
the suspended cells and in the samples taken from the 
growth medium during the incubation with the dsRNA 
was measured in a Packard y-counter. The extent of 
“Cr released from the cells due to the lysis was 
expressed as % of the total label originally present in 
the culture. The total amount of the label was the 
same in interferon-treated and non-treated cultures. 
The experiments were run in duplicates; variation 
between the duplicates was lo-20%. 
2.2. Measurement of viralgrowth inhibition by inter- 
feron 
Confluent human foreskin fibroblasts were pre- 
treated for 24 h with interferon and then infected with 
vesicular stomatitis virus (2 p.f.u./cell). After 12 h, 
samples of the growth medium were taken off the cells 
and frozen. The amount of viruses in these samples 
was later estimated by plaque-assay on mouse L-929 
cells. 
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2.3. Materials 
Sodium [SICr]chromate was obtained from the 
Radiochemical Center, Amersham; poly(rI):(rC) from 
P.L. Lab. Hydrocortisone succinate and dexametha- 
sane phosphate from NV Organon Oss. Testosterone 
and progesterone from Ikapharm, Ramat Gan. Indo- 
methacine from Asia, Israel. Methyl-isobutylxanthine 
from Alldrich. Cyclic AMP derivatives and 8-bromo 
AMP from Sigma. PGEl was kindly made available to 
us by Dr G. Pike of the Upjohn Co., Kalamazoo, MI. 
Interferon was induced in the FSl 1 fibroblasts by 
poly(rI):(rCj [1,4] and purified on carboxymethyl 
cellulose column to an activity of -IO7 units/mg 
protein. 
3. Results 
Interferon-treated human foreskin fibroblasts start 
to lyse a few hours after they are exposed to dsRNA. 
To quantitate the extent of cell lysis, we measured 
(fig.1) ‘lCr release from prelabeled fibroblasts [ 11,131. 
In the absence of dsRNA there is a slow “Cr release 
not accompanied by visible lysis. Cell lysis was there- 
fore estimated by the % of 51Cr released in the presence 
of dsRNA minus the ‘lCr released in its absence (net 
‘lCr released). Only cells pretreated with interferon 
show a high rate of lysis (fig.1) and continue to ly:e 
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t’ig.2. Inhibition by corticosteroids of tile dsRNA-induced 
cytolysis. Lysis was induced as in section 2. The net “Cr 
released (see text) during 9.5 h continuous incubation with 
dsRNA is shown. Relcase without dsRNA (SC’) was sub- 
tracted. Steroids were added to the cells 15 h before dsRNA 
and re-added together with the dsRNA. (m) dexamethasonc 
phosphate; (0) hydrocortisone succinate: (n) testosterone; 
(v) progesterone. (The latter t\vo in 0.08%; ethanol which had 
no effect on the lysis.) 
Fig. I. Kinetics of dsRNA-induced cytolysis of interferon- 
treated cells. Cytolysis was induced as in section 2 except 
that 2 h after its addition dsRNA was removed, cells were 
washed and dsRNA was added back to only part of the cul- 
tures. (.) Inteferon pretreated and continuous prescncc of 
dsRNA; (u) interferon pretreated but dsRNA for only 2 h; 
(0) not treated with interferon and continuous presence 
of dsRNA; (3) not treated with interferon and dsRNA for 
2 h; (A) not treated with interferon and no dsRNA. 
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even if dsRNA is removed after 2 h. Without inter- 
feron pretreatment, cell lysis is low and depends on 
continuous exposure to dsRNA (fig.1). 
Pretreatment of the interferon-treated cells with 
corticosteroids prevented the cytolysis by dsRNA. 
Significant protection against the cytolysis was seen 
with as low as 5 X lo-” M dexamethasone or hydro- 
cortisone (fig.2). In contrast, testosterone and pro- 
gesterone, which donot have anti-inflammatory 
action, did not show any protection (fig.2). 
It was shown [ 131 that dsRNA stimulates prosta- 
glandin E synthesis in human foreskin fibroblasts. 
Similarly to the cell lysis shown in fig.1, this effect of 
dsRNA is strongly potentiated by interferon pretreat- 
ment (D. W., R. Ben-Dori, unpublished data) and pre- 
vented by corticosteroids [ 131. Prostaglandin E is, 
however, not the cause of cell lysis; on the contrary, 
addition of prostaglandin E inhibited the dsRNA- 
induced lysis of interferon-treated cells (table 1). 
Moreover, indomethacine which inhibits the conver- 
sion of arachidonic acid to prostaglandin, increased 
the cell lysis. Prostaglandin E increases the level of 
cyclic AMPin fibroblasts by stimulating their adenylate 
cyclase [ 14,151 and indeed protection against cyto- 
lysis was also seen with several other agents that 
elevate CAMP in the cells. These include (table 1): 
Table 1 
Prevention of cell lysis by agents that elevate cyclic AMP 
~__ 
Expt Addition Net “Cra 
released (%) 
_. ___ --__ 
1. None 22 
PGE, 10 &ml 3 
Indomethacin 1 pg/ml 41 
Isoproterenol 10-5M 8 
Methyl-isobutylxanthine 100 pg/ml 2 
8-bromo-cyclic AMP 1mM 1 
2. None 46 
8-bromo-cyclic CAMP 1 mM 3 
8-bromo AMP 1mM 49 
Dibutyryl cyclic AMP 1 mM 3 
Sodium butyrate 1mM 50 
___~_ _~___ ______- 
a “Cr release in the absence of dsRNA of 9% in expt 1 and 
8% in expt 2 was subtracted. In the absence of dsRNA there 
was no stimulation of cytolysis by indomethacin 
Cytolysis was induced by incubation of interferon-treated cells 
for 8.5 h with poly(rI):(rC) as in fig.]. Reagents mentioned 
above were added 5 min before the addition of dsRNA 
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(i) Isoproterenol which stimulates the adenylate 
cyclase through /3-adrenergic receptors on these 
cells [16]; 
(ii) The cyclic nucleotide phosphodiesterase-inhibitor 
methylisobutylxanthine; 
(iii) The CAMP derivatives Cbromo-CAMP and dibu- 
tyryl CAMP. 
We verified that 8-bromo-AMP or butyric acid alone 
were inactive (table 1). 
The inhibition by CAMP of the dsRNA-induced 
cytolysis in interferon-treated cells was rapid and could 
be induced even after the beginning of the incubation 
with dsRNA (table 2). Surprisingly, preincubation of 
cells with 8-bromo-CAMP for 15 h reduced its inhib- 
itory effect on cytolysis (table 2), suggesting that this 
protective effect of CAMP is subject to ‘desensitiza- 
tion’. In addition to corticosteroids and CAMP, calf 
serum protected the interferon-treated cells against 
cytolysis induced by dsRNA. The protection by serum 
was again rapid (table 2). In contrast, protection by 
corticosteroids, even at high concentrations, required 
prolonged pretreatment (table 2). The serum factor(s) 
that protect interferon-treated cells against dsRNA- 
induced cytolysis are not, therefore, corticosteroids; 
it is also unlikely that serum protection is related to 
CAMP since serum decreases the CAMP level in fibro- 
blasts [ 171. This was recently confirmed by purifica- 
Table 2 
Time course of the protection against the cytolysis 
Addition Time (11) of addition Net “Cr 
relative to dsRNA released 
--___ ____ 
None 31 
8-bromo cyclic 
AMP (1 mM) -15 13 
- 1 0 
+2 3 
Serum 10% 0 3 
+2 1 
Dexamethasone 
(5 x IO-’ M) -15 0 
- 1 15 
0 15 
+2 20 
__~_ 
Cytolysis was induced by incubation of interferon-treated 
cells for 8 h with poly(rI):(rC) as in fig.]. “Cr released in the 
absence of dsRNA (11%) was subtracted 
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Table 3 
Antiviral effect of interferon in the presence of dexamethasone and of 
cyclic AMP derivatives 
..___ 
Pretreatment Virus yield (log p.f.u./l O6 cells) 
No interferon 5 U/ml interferon 
_ 12.1 3.9 
Dexamethasone (5 X IO-’ M) 12.0 4.0 
8-bromo cyclic AMP (1 mM) 12.7 3.9 
Dibutyryl-cyclic AMP (1 mM) 13.1 4.0 
Confluent human foreskin fibroblasts were pretreated for 24 h with interferon, 
then infected with vesicular stomatitis virus (2 p.f.u./cell). After 12 h, samples 
of the growth medium were taken off the cells and frozen. The amount of viruses 
in these samples was later estimated by plaque-assay on mouse L-929 cells. Dexa- 
methasone was added 12 h and cyclic AMP derivatives 2 h before the infection 
tion of the protective factor from serum (unpublished 
data). 
Effects of hormones and CAMP on the antiviral 
effects of interferon were reported [ 18,191. To verify 
that corticosteroids or CAMP do not have a general 
inhibitory effect on interferon functions in our system, 
we tested again these agents on the antiviral function 
of interferon. As shown in table 3, dexamethasone, 
8-bromo-CAMP and dibutyrylcyclic AMP, in concen- 
trations in which they fully protected interferon- 
treated cells from the cytolysis induced by dsRNA, 
did not decrease the inhibition by interferon of vesic- 
ular stomatitis virus multiplication. 
4. Discussion 
The mechanism by which dsRNA can cause cell 
lysis in interferon-treated cultures is not known. 
Several dsRNA-dependent enzymes are induced by 
interferon [20], and interferon enhances the ability 
of dsRNA to induce new interferon (priming) [3]. A 
relation between these phenomena is possible, but 
is far from clear. The one effect of dsRNA that, at 
present, may be related to cytolysis, is the induction 
of prostaglandin formation in fibroblasts. Both are 
inhibited by corticosteroids [ 131 and strongly poten- 
tiated by pretreatment with interferon (unpublished 
observations). A possible model for the relation 
between the induction of prostaglandin and cytolysis 
is shown in fig.3. It is suggested that an increased lipid 
Cytdysls 
lnterferol 0 , 
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Fig.3. Model for the relation between induction of cytolysis 
and induction of prostaglandin synthesis by dsRNA. Broken 
arrows denote inhibitory effects. Set text for other details. 
hydrolysis in the cellular membrane leads both to cell 
lysis and, as was shown for several agents [21-231, to 
release of arachidonic acid and to prostaglandin syn- 
thesis. Corticosteroids inhibit prostaglandin synthesis 
by preventing membrane lipid hydrolysis [2 1~.231, and 
this could explain their anti-cytolytic activity. Indo- 
methacin, does not prevent lipid hydrolysis but inhibits 
the conversion of arachidonic acid to prostaglandin 
[21-231. Inhibition by indomethacin of prostaglandin 
formation in the course of cytolysis, would prevent 
the elevation of cellular CAMP that the prostaglandins 
produce and, in this way, increase the rate of cytolysis. 
Prostaglandin synthesis, in this model, would be a 
feedback inhibitor of cell lysis by dsRNA in inter- 
feron-treated cells. 
Interferon increases not only the sensitivity of cells 
to the cytotoxicity of dsRNA but also cell sensitivity 
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to cytolysis by some viruses [6 81 and also by killer 
lymphocytes [25]. Cell multiplication [26] and 
motility(J. Werenne, M. R., D. W., unpublished obser- 
vations) are inhibited by interferon. The damage 
caused by these various ‘anticellular’ effects of inter- 
feron seem, in some cases, to overweigh its protective 
‘antiviral’ effects [9]. The fact that corticosteroids, 
CAMP and serum, can counteract the increased sensitiv- 
ity of the interferon-treated cells to dsRNA without 
decreasing the antiviral effect, raises the possibility 
that many anticellular effects of interferon could be 
specifically reduced by hormones. Aspirin and indo- 
methacin may, on the other hand, potentiate these 
anticellular effects. The hormonal control of inter- 
feron and of dsRNA actions should, therefore, be 
carefully examined. Such studies may clarify the 
mechanisms involved and improve the practical use 
of the interferon and of its inducers. 
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